Diabetes News
PITTSBURGH, March 3, 2005 (UPMC) – Physicians at the University of Pittsburgh School of Medicine are beginning a research study to determine if a new medication can lower blood sugar in people with type 2 diabetes.
“The aim of this study is to determine if this investigational drug, called LAF237, can reduce fasting and after-meal blood glucose,” said David E. Kelley, M.D., professor of medicine in the division of endocrinology and metabolism at the University of Pittsburgh School of Medicine and principal investigator in the study.
The randomized, double blinded, placebo controlled research study will enroll 22 men and women between 18 and 65 years of age with type 2 diabetes and will last about 16 weeks. People currently being treated with insulin are excluded from the study.
For more information on the study and to find out if you qualify, call
Juliet Mancino, M.S., R.D., C.D.E., primary study coordinator at (412) 692-2970. Those participants who complete the study will be compensated.